Axsome Therapeutics, Inc. (AXSM) Stock
NMQ · AXSM
207.78
Fundamentals
Market cap
$10.88B
Price / Earnings ratio
-58.6x
Price / Sales ratio
14.4x
Price / Book ratio
134.7x
Return on assets
-0.3%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Axsome Therapeutics, Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
SectorHealthcare
IndustryBiotechnology
Employees1,346
CEODr. Herriot Tabuteau M.D.
IPO DateNov 19, 2015
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Herriot Tabuteau M.D. | Founder, Chairman, CEO & President | 1968 |
| Mr. Nick Pizzie CPA, M.B.A. | Chief Financial Officer | 1975 |
| Mr. Mark L. Jacobson M.A. | Chief Operating Officer | 1983 |
| Mr. Hunter Murdock Esq. | General Counsel & Secretary | 1980 |
| Mr. Ari Maizel M.B.A. | Chief Commercial Officer | 1979 |
| Darren Opland | Director of Corporate Communications | — |
Fundamentals
Valuation
Market cap$10.88B
Price-to-sales ratio14.45
Price-to-book value134.74
Price-earnings ratio-58.60
Return on Equity-260.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-3.74
Income Statement
Average volume583,475
EBITDA$-170.94M
1 year high (52w)$260.19
1 year low (52w)$114.91
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



